Literature DB >> 9275350

P53 gene abnormalities in osteosarcoma.

W Guo1, X Wang, C Feng.   

Abstract

OBJECTIVE: The P53 tumor suppressor gene shows the most frequent genetic alteration in human tumors. Mutation, deletion and rearrangement of P53 gene have been found in several types of neoplasm including osteosarcoma. The present study is to clarify the status of abnormalities of this gene in osteosarcoma in China.
MATERIALS AND METHODS: Forty-six osteosarcomas were collected from 32 male and 14 female patients aged 20.6 years on average. Eight patients had lung metastasis. Immunohistochemistry, Southern blot and contrast flow cytometry were used for the study.
RESULTS: Twenty-seven of 46 (58.7%) osteosarcoma specimens showed strongly positive reaction to the MoAb BP53-12 staining (+2 - +3), which indicated overexpression of P53 protein in osteosarcoma. Contrast study with DNA flow cytometry made on osteosarcoma showed that most of the tumors with strongly positive P53 have higher DNA content than those of negative ones. Alterations of the restriction pattern of the P53 gene were detected in 4 of 20 osteosarcomas in the Hind III group and 3 of 24 in the Eco R I group. Three of them were part or whole deletion of the gene and five of them had extraband which indicated rearrangement of the gene.
CONCLUSIONS: The results of this study showed that overexpression of P53 oncoprotein is one of the most frequent genetic changes in osteosarcoma and P53 oncoprotein expression analysis could be a prognostic parameter in osteosarcoma. P53 gene abnormalities play an important role in the development of transformation and proliferation of osteosarcoma cells.

Entities:  

Mesh:

Year:  1996        PMID: 9275350

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  6 in total

Review 1.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

Review 2.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

3.  P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells.

Authors:  Yifu Sun; Peng Xia; Haipeng Zhang; Biao Liu; Ying Shi
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

Review 4.  Osteosarcoma Overview.

Authors:  Brock A Lindsey; Justin E Markel; Eugenie S Kleinerman
Journal:  Rheumatol Ther       Date:  2016-12-08

5.  Verteporfin disrupts multiple steps of autophagy and regulates p53 to sensitize osteosarcoma cells.

Authors:  Heena Saini; Harshita Sharma; Sudeshna Mukherjee; Shibasish Chowdhury; Rajdeep Chowdhury
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

Review 6.  MicroRNAs and Potential Targets in Osteosarcoma: Review.

Authors:  Valerie B Sampson; Soonmoon Yoo; Asmita Kumar; Nancy S Vetter; E Anders Kolb
Journal:  Front Pediatr       Date:  2015-08-24       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.